SCHEDULE 13G/A 0001193125-21-038641 0000924223 XXXXXXXX LIVE 5 Common Stock 12/31/2024 0001701541 Black Diamond Therapeutics, Inc. 09203E105 One Main Street, 14th Floor Cambridge MA 02142 Rule 13d-1(c) BB Biotech AG a V8 0.00 8517839.00 0.00 8517839.00 8517839.00 N 15.1 HC CO Biotech Growth N.V. a P8 0.00 8517839.00 0.00 8517839.00 8517839.00 N 15.1 CO Black Diamond Therapeutics, Inc. One Main Street 10th Floor Cambridge, MA, 02142 BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Growth N.V. ("Biotech Growth") BB Biotech: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland Biotech Growth: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curacao BB Biotech: Switzerland Biotech Growth: Curacao Y 8,517,839 15.1% 0 8,517,839 0 8,517,839 Y Y N This statement is filed jointly by BB Biotech and Biotech Growth. Biotech Growth is a wholly-owned subsidiary of BB Biotech. Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Exhibit A: Agreement by and between BB Biotech AG and Biotech Growth N.V. with respect to the filing of this disclosure statement.* *Previously filed as an exhibit to BB Biotech AG and Biotech Growth N.V.'s Schedule 13G filed with the Securities and Exchange Commission on February 11, 2021. BB Biotech AG /s/ Martin Gubler 02/12/2025 /s/ Ivo Betschart 02/12/2025 Biotech Growth N.V. /s/ Jan Bootsma 02/12/2025 /s/ Hugo von Neutegem 02/12/2025